Want to see ABEO full AI Analyst Report?
ABEO Stock Chart & Stats
$5.50
-$0.15(-2.50%)
At close: 4:00 PM EST
$5.50
-$0.15(-2.50%)
Day’s Range― - ―
52-Week Range$4.00 - $7.54
Previous CloseN/A
Volume71.38K
Average Volume (3M)1.36M
Market Cap
$398.97M
Enterprise Value$108.56
Total Cash (Recent Filing)$168.27M
Total Debt (Recent Filing)$23.17M
Price to Earnings (P/E)5.4
Beta1.53
Next Earnings
Aug 12, 2026EPS Estimate
-0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.28
Shares Outstanding56,995,144
10 Day Avg. Volume1,480,026
30 Day Avg. Volume1,358,110
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)1.75
Price to Sales (P/S)47.95
P/FCF Ratio-3.31
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$19.75Price Target Upside259.09% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.72
Revenue Forecast (FY)$66.29M
Bulls Say, Bears Say
Bulls Say
Commercial Launch TractionSustained early commercial revenue demonstrates the company has moved beyond research-stage milestones into recurring product flows. Durable launch traction—if maintained as QTCs scale—supports predictable unit economics and a pathway to cover fixed costs over the next 2–6 months.
Payer CoverageExtensive commercial payer coverage is a structural advantage for adoption of a high-cost gene therapy. Broad coverage reduces reimbursement risk, shortens sales cycles for insured patients and supports sustained revenue realization as the treatment network expands.
Manufacturing Reliability & Gross MarginConsistent manufacturing yields and a swift turnaround establish operational reliability critical for repeatable treatments. Coupled with solid gross margins, this supports scalable economics and reduces unit cost volatility as volumes grow across QTCs.
Bears Say
Persistent Cash BurnLarge negative operating and free cash flows indicate the company remains reliant on external financing to sustain operations. Over months this raises dilution and refinancing risk, limits discretionary R&D or commercial spend, and constrains long-term financial flexibility.
Operating Losses & Earnings QualityPersistent operating deficits and a disconnect between reported net income and cash generation reflect an unstable earnings base. Until operating profitability is achieved, reported profits may not translate to cash, complicating forecasting and capital allocation decisions.
Operational Rollout FrictionLengthy, variable onboarding and biopsy lead times materially slow geographic expansion and revenue scaling. These structural operational constraints increase uncertainty in throughput forecasts and extend the timeline to achieve steady-state per‑center revenue.
Abeona Therapeutics News
ABEO FAQ
What was Abeona Therapeutics Inc’s price range in the past 12 months?
Abeona Therapeutics Inc lowest stock price was $4.00 and its highest was $7.54 in the past 12 months.
What is Abeona Therapeutics Inc’s market cap?
Abeona Therapeutics Inc’s market cap is $398.97M.
When is Abeona Therapeutics Inc’s upcoming earnings report date?
Abeona Therapeutics Inc’s upcoming earnings report date is Aug 12, 2026 which is in 23 days.
How were Abeona Therapeutics Inc’s earnings last quarter?
Abeona Therapeutics Inc released its earnings results on May 13, 2026. The company reported -$0.3 earnings per share for the quarter, beating the consensus estimate of -$0.335 by $0.035.
Is Abeona Therapeutics Inc overvalued?
According to Wall Street analysts Abeona Therapeutics Inc’s price is currently Undervalued.
Does Abeona Therapeutics Inc pay dividends?
Abeona Therapeutics Inc does not currently pay dividends.
What is Abeona Therapeutics Inc’s EPS estimate?
Abeona Therapeutics Inc’s EPS estimate is -0.23.
How many shares outstanding does Abeona Therapeutics Inc have?
Abeona Therapeutics Inc has 56,995,144 shares outstanding.
What happened to Abeona Therapeutics Inc’s price movement after its last earnings report?
Abeona Therapeutics Inc reported an EPS of -$0.3 in its last earnings report, beating expectations of -$0.335. Following the earnings report the stock price went up 0.528%.
Which hedge fund is a major shareholder of Abeona Therapeutics Inc?
Currently, no hedge funds are holding shares in ABEO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Abeona Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$19.75 (259.09% Upside)
$19.75 (259.09% Upside)
Blogger Sentiment
Bullish
ABEO Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 40.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 4.7%
Last 30 Days ▼ 4.0%
Last 30 Days ▼ 4.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
5.58%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
99.76%
Trailing 12-Months
Company Description
Abeona Therapeutics Inc
Abeona Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, focused on creating innovative gene and cell therapies to address severe and uncommon genetic diseases. Its leading program, EB-101, an autologous gene-corrected cell therapy, is presently in a Phase III clinical trial for treating recessive dystrophic epidermolysis bullosa. The company's pipeline also features several other promising therapies: ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A. ABO-201, intended for CLN3 disease. ABO-401, developed to treat cystic fibrosis. ABO-50X, aimed at various genetic eye disorders. Additionally, Abeona is advancing AAV-based gene therapy solutions through its proprietary AIM vector platform. The company, which was founded in 1974 and is headquartered in New York, New York, changed its name to Abeona Therapeutics Inc. in June 2015, having previously been known as PlasmaTech Biopharmaceuticals, Inc.
ABEO Stock 12 Month Forecast
Average Price Target
$19.75
▲(259.09% Upside)
Technical Analysis
Ownership Overview
6.31% Insiders
6.74% Mutual Funds
0.63% Other Institutional Investors
77.61% Public Companies and
Individual Investors